The enhancement of M13 phage titration by optimizing the origin of replication

Mohammad Hossein Darvishali , Mahmood Fadaie, Hossein Khanahmad

Abstract


Background and purpose: M13KO7, a modified M13 phage variant, carries the p15A replication origin and Tn903 kanamycin resistance gene. This study aimed to optimize M13KO7's replication by substituting the p15A origin with the higher-copy pMB1 origin (500-700 copy numbers).

Experimental approach: A 6431-nucleotide fragment from the M13KO7 plasmid lacking the p15A replication origin and kanamycin resistance gene was amplified using a long polymerase chain reaction (PCR). The modified M13AMB1 plasmid was created by adding adenine to the 3’ ends of this fragment and ligating it to the pMB1-containing fragment using T/A cloning. Afterward, to prepare the phage, pM13AMB1 was transformed into E. coli TG1 bacteria, and then, using the PEG-NaCl precipitation, the modified phage was propagated. The modified phage titer was determined utilizing the serial dilution and the qPCR methods, compared with the M13KO7 phage.

Findings/Results: The results showed that in the serial dilution method, the titers of modified phage and M13KO7 phage were 4.8 × 1014 and 7 × 1012 pfu/mL, respectively. Besides, the phage titer calculated by the qPCR method for the modified phage was equal to 1.3 × 109 pfu/mL, whereas it was 4.08 × 108 pfu/mL for the M13KO7 phage.

Conclusion and implications: This study provides evidence that replication origin replacement led to a significant increase in phage titers. It highlights the importance of replication optimization for molecular biology applications.


Keywords


Bacteriophage; M13 Phage; Phage titer; Replication origin.

Full Text:

PDF

References


Chang C, Guo W, Yu X, Guo C, Zhou N, Guo X, et al. Engineered M13 phage as a novel therapeutic bionanomaterial for clinical applications: from tissue regeneration to cancer therapy. Mater Today Bio. 2023;20:1006121,1-16.DOI: 10.1016/j.mtbio.2023.100612.

Wang R, Li HD, Cao Y, Wang ZY, Yang T, Wang JH. M13 phage: a versatile building block for a highly specific analysis platform. Anal Bioanal Chem. 2023;415(18):3927-3944.DOI: 10.1007/s00216-023-04606-w.

González-Mora A, Hernández-Pérez J, Iqbal HMN, Rito-Palomares M, Benavides J. Bacteriophage-based vaccines: a potent approach for antigen delivery. Vaccines. 2020;8(3):504,1-24.DOI: 10.3390/vaccines8030504.

Jaroszewicz W, Morcinek-Orłowska J, Pierzynowska K, Gaffke L, Wȩgrzyn G. Phage display and other peptide display technologies. FEMS Microbiol Rev. 2022;46(2):1-25.DOI: 10.1093/femsre/fuab052.

Bazan J, Całkosiñski I, Gamian A. Phage display a powerful technique for immunotherapy: introduction and potential of therapeutic applications. Hum Vaccines Immunother. 2012;8(12):1817-1828.DOI: 10.4161/hv.21703.

Fadaie M, Dianat-Moghadam H, Ghafouri E, Naderi S, Darvishali MH, Ghovvati M, et al. Unraveling the potential of M13 phages in biomedicine: advancing drug nanodelivery and gene therapy. Environ Res. 2023;238(P1):117132.DOI: 10.1016/j.envres.2023.117132.

Méndez-Scolari JE, Florentín-Pavía MM, Mujica MP, Rojas N, Sotelo PH. A qPCR targeted against the viral replication origin designed to quantify total amount of filamentous phages and phagemids. Indian J Microbiol. 2019;59(3):365-369.DOI: 10.1007/s12088-019-00798-x.

Camps M. Modulation of ColE1-like plasmid replication for recombinant gene expression. Recent Pat DNA Gene Seq. 2010;4(1):58-73.DOI: 10.2174/187221510790410822.

Kendall Morgan MP. Plasmids 101. In: Plasmid 101. Adgene.2023.

Available from: addgene.org.

Selzer G, Som T, Itoh T, Tomizawa J. The origin of replication of plasmid p15A and comparative studies on the nucleotide sequences around the origin of related plasmids. Cell. 1983;32(1):119-129.DOI: 10.1016/0092-8674(83)90502-0.

Chang A, Chau V, Landas J, Pang Y. Preparation of calcium competent Escherichia coli and heat-shock transformation. J Exp Microbiol Immunol. 2017;1:22-25.

Hosseini N, Khanahmad H, Nasr Esfahani B, Bandehpour M, Shariati L, Zahedi N, et al. Targeting of cholera toxin A (ctxA) gene by zinc finger nuclease: pitfalls of using gene editing tools in prokaryotes. Res Pharm Sci. 2020;15(2):182-190.DOI: 10.4103/1735-5362.283818.

Reddy P, McKenney K. Improved method for the production of M13 phage and single-stranded DNA for DNA sequencing. Biotechniques. 1996;20(5):854-860.DOI: 10.2144/96205st05.

Ács N, Gambino M, Brøndsted L. Bacteriophage enumeration and detection methods. Front Microbiol. 2020;11:594868,1-7.DOI: 10.3389/fmicb.2020.594868.

Boshtam M, Asgary S, Rahimmanesh I, Kouhpayeh S, Naderi J, Hejazi Z, et al. Display of human and rabbit monocyte chemoattractant protein-1 on human embryonic kidney 293T cell surface. Res Pharm Sci. 2018;13(5):430-439.DOI: 10.4103/1735-5362.236836.

Kadiri VM, Alarcón-Correa M, Ruppert J, Günther JP, Bill J, Rothenstein D, et al. Genetically modified M13 bacteriophage nanonets for enzyme catalysis and recovery. Catalysts. 2019;9(9):1-10.DOI: 10.3390/catal9090723.

Ghosh D, Kohli AG, Moser F, Endy D, Belcher AM. Refactored M13 bacteriophage as a platform for tumor cell imaging and drug delivery. ACS Synth Biol. 2012;1(12):576-582.DOI: 10.1021/sb300052u.

Wong S, Jimenez S, Slavcev RA. Construction and characterization of a novel miniaturized filamentous phagemid for targeted mammalian gene transfer. Microb Cell Fact. 2023;22(1):124,1-14.DOI: 10.1186/s12934-023-02135-w.

Kiga K, Tan XE, Ibarra-Chávez R, Watanabe S, Aiba Y, Sato’o Y, et al. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria. Nat Commun. 2020;11(1):1-11.DOI: 10.1038/s41467-020-16731-6.

Kok DN, Turnbull J, Takeuchi N, Tsourkas PK, Hendrickson HL. In vitro evolution to increase the titers of difficult bacteriophages: RAMP-UP protocol. Phage. 2023;4(2):68-81.DOI: 10.1089/phage.2023.0005.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.